AMRN- I am not sure what the short numbers are, but I believe they covered in the 5's after the company sold shares as per Adam Feuerstein's article couple of months ago. I had AMRN earlier but at this point I am not eager to get in. It is sporting over a Billion dollar Market Cap with sales in the <10 million per quarter (though that was the first quarter and prescriptions are still rising). Plus with the patent issue still hanging over the risk reward ratio is not too enticing now. It is however a momentum stock with a great following, so that might do wonders but be careful and watch it closely.